目的 观察癃闭舒胶囊联合罗红霉素治疗慢性前列腺炎的临床疗效。方法 选取2016年7月-2017年6月在焦作煤业（集团）有限责任公司中央医院治疗的慢性前列腺炎患者106例，随机分为对照组和治疗组，每组各53例。对照组患者口服罗红霉素胶囊，150 mg/次，2次/d；治疗组在对照组基础上口服癃闭舒胶囊，3粒/次，2次/d。两组患者均治疗4周。观察两组患者临床疗效，同时比较治疗前后两组患者肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）水平及慢性前列腺炎症状指数（NIH-CPSI）评分。结果 治疗后，对照组临床总有效率为77.36%，显著低于治疗组的92.45%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清和前列腺液中TNF-α和IL-6水平及NIH-CPSI评分均显著降低，同组比较差异具有统计学意义（P<0.05）；且治疗组患者上述指标水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 癃闭舒胶囊联合罗红霉素治疗慢性前列腺炎临床疗效确切，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Longbishu Capsules combined with roxithromycin in treatment of chronic prostatitis. Methods Patients (106 cases) with chronic prostatitis in Jiaozuo Coal Industry Group Central Hospital from July 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Roxithromycin Capsules, 150 mg/time, twice daily. Patients in the treatment group were po administered with Longbishu Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the TNF-α levels, IL-6 levels, NIH-CPSI scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 77.36%, which was significantly lower than 92.45% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the TNF-α and IL-6 levels of serum and prostatic fluid and NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the indicators in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Longbishu Capsules combined with roxithromycin in treatment of chronic prostatitis has significant clinical efficacy, which has a certain clinical application value.